A. Buness, A. Roth, A. Herrmann, O. Schmitz, H. Kamp u. a.: Identification of Metabolites, Clinical Chemistry Markers and Transcripts Associated with Hepatotoxicity. In: PLoS ONE. 9, 2014, S. e97249. doi:10.1371/journal.pone.0097249
C. L. Bellac, R. S. Coimbra, S. Christen, S. L. Leib: Pneumococcal meningitis causes accumulation of neurotoxic kynurenine metabolites in brain regions prone to injury. In: Neurobiol. Dis. Band24, Nr.2, November 2006, S.395–402, doi:10.1016/j.nbd.2006.07.014, PMID 16956766.
C. J. Clark, G. M. Mackay, G. A. Smythe, S. Bustamante, T. W. Stone, R. S. Phillips: Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. In: Infection and Immunity. Band73, Nr.8, August 2005, S.5249–5251, doi:10.1128/IAI.73.8.5249-5251.2005, PMID 16041050, PMC 1201246 (freier Volltext).
F. Giorgini, P. Guidetti, Q. Nguyen, S. C. Bennett, P. J. Muchowski: A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. In: Nature Genetics. Band37, Nr.5, Mai 2005, S.526–531, doi:10.1038/ng1542, PMID 15806102, PMC 1449881 (freier Volltext).
M. Hamann, S. E. Sander, A. Richter: Effects of the kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dt sz mutant. In: Eur J Pharmacol. Band586, Nr.1-3, Mai 2008, S.156–159, doi:10.1016/j.ejphar.2008.02.052, PMID 18353306.
L. Grégoire, A. Rassoulpour, P. Guidetti u. a.: Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. In: Behav. Brain Res. Band186, Nr.2, Januar 2008, S.161–167, doi:10.1016/j.bbr.2007.08.007, PMID 17868931.
B. Poeggeler, A. Rassoulpour, H. Q. Wu, P. Guidetti, R. C. Roberts, R. Schwarcz: Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity. In: Neuroscience. Band148, Nr.1, August 2007, S.188–197, doi:10.1016/j.neuroscience.2007.05.033, PMID 17629627, PMC 2034343 (freier Volltext).
nih.gov
ncbi.nlm.nih.gov
C. L. Bellac, R. S. Coimbra, S. Christen, S. L. Leib: Pneumococcal meningitis causes accumulation of neurotoxic kynurenine metabolites in brain regions prone to injury. In: Neurobiol. Dis. Band24, Nr.2, November 2006, S.395–402, doi:10.1016/j.nbd.2006.07.014, PMID 16956766.
C. J. Clark, G. M. Mackay, G. A. Smythe, S. Bustamante, T. W. Stone, R. S. Phillips: Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition. In: Infection and Immunity. Band73, Nr.8, August 2005, S.5249–5251, doi:10.1128/IAI.73.8.5249-5251.2005, PMID 16041050, PMC 1201246 (freier Volltext).
F. Giorgini, P. Guidetti, Q. Nguyen, S. C. Bennett, P. J. Muchowski: A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. In: Nature Genetics. Band37, Nr.5, Mai 2005, S.526–531, doi:10.1038/ng1542, PMID 15806102, PMC 1449881 (freier Volltext).
M. Hamann, S. E. Sander, A. Richter: Effects of the kynurenine 3-hydroxylase inhibitor Ro 61-8048 after intrastriatal injections on the severity of dystonia in the dt sz mutant. In: Eur J Pharmacol. Band586, Nr.1-3, Mai 2008, S.156–159, doi:10.1016/j.ejphar.2008.02.052, PMID 18353306.
L. Grégoire, A. Rassoulpour, P. Guidetti u. a.: Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. In: Behav. Brain Res. Band186, Nr.2, Januar 2008, S.161–167, doi:10.1016/j.bbr.2007.08.007, PMID 17868931.
B. Poeggeler, A. Rassoulpour, H. Q. Wu, P. Guidetti, R. C. Roberts, R. Schwarcz: Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity. In: Neuroscience. Band148, Nr.1, August 2007, S.188–197, doi:10.1016/j.neuroscience.2007.05.033, PMID 17629627, PMC 2034343 (freier Volltext).